GLP-1 Innovation and Oversight Shaping the Future of Therapeutic Access

Buyer Beware: How Weak Oversight of Compounded GLP-1s Threatens Patient Safety

  • Play
  • Sep 16 2025 Duration: 60 mins

Presented by

Peter J. Pitts, President of the Center for Medicine in the Public Interest and former FDA Associate Commissioner

About this talk

Despite the end of the FDA-declared shortage, compounded versions of semaglutide and tirzepatide remain widely available. Compounded GLP-1s, often manufactured without FDA oversight using foreign-sourced ingredients, pose growing safety risks and are being marketed alongside FDA-approved brands like Wegovy, Ozempic, Zepbound and Mounjaro.

In this session, Peter J. Pitts, President of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, presents findings from his July 2025 report, "FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding."

What you’ll learn:

• Regulatory and enforcement gaps behind mass-produced GLP-1 knockoffs.
• Rising safety concerns associated with unapproved compounded drugs.
• Steps regulators must take to restore market integrity and protect patients.

Share on:

Available on demand